LU AA34893

Drug Profile

LU AA34893

Alternative Names: LU AA 34893

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Class Antidepressants
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bipolar disorders; Major depressive disorder

Most Recent Events

  • 04 Mar 2010 Lundbeck discontinues LU AA34893 development programme
  • 25 Nov 2009 Lundbeck is investigating preclinical findings in order to determine future development
  • 18 Nov 2009 Discontinued - Phase-II for Bipolar disorders in Asia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top